Shares of Revance Therapeutics Inc. (NASDAQ:RVNC) traded up 2.9% during mid-day trading on Thursday . The stock traded as high as $15.42 and last traded at $15.30, with a volume of 53,315 shares changing hands. The stock had previously closed at $14.87.

Several analysts have issued reports on the company. Brean Capital reaffirmed a “buy” rating on shares of Revance Therapeutics in a research report on Saturday, June 4th. SunTrust Banks Inc. dropped their target price on Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, June 14th. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, July 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $35.00 target price (down previously from $54.00) on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Finally, Guggenheim reaffirmed a “buy” rating and set a $55.00 target price on shares of Revance Therapeutics in a research report on Tuesday, June 14th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $39.60.

The firm’s market capitalization is $437.23 million. The company’s 50 day moving average is $13.84 and its 200 day moving average is $16.87.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.02. The business earned $0.80 million during the quarter, compared to the consensus estimate of $0.06 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. Equities research analysts expect that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current year.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.